Hikari Power’s Adamas Pharmaceuticals ADMS Stock Holding History

Hikari Power’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-30,000	Closed	-$601K	–	134
2018 Q3	$601K	Hold	30,000	–	–	0.06%	75
2018 Q2	$775K	Hold	30,000	–	–	0.09%	70
2018 Q1	$717K	Hold	30,000	–	–	0.08%	69
2017 Q4	$1.02M	Hold	30,000	–	–	0.12%	60
2017 Q3	$635K	Buy	+30,000	New	+$550K	0.08%	63

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Hikari Power's ADMS Position: Q4 2018 in Review

Hikari Power sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 30,000 shares — an estimated $601K sold.

Hikari Power first reported a position in ADMS in Q3 2017 and held it in 5 quarters. The position peaked at $1.02M in Q4 2017. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

Hikari Power reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Hikari Power sold 30,000 Adamas Pharmaceuticals shares in Q4 2018, an estimated $601K.
Hikari Power first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 5 quarters.
Hikari Power's Adamas Pharmaceuticals position peaked at $1.02M in Q4 2017.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Hikari Power's 13F filing for Q4 2018, filed 29 Jan 2019.